Clinical Trial Update: A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia. [Phase 3]

View source ↗

Summary

Phase 3 study of Bonviva (ibandronate) given once monthly in postmenopausal women with osteopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-menopausal Osteopenia

Drugs mentioned

• Bonviva (ibandronic acid)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Post-Menopausal Osteopenia | Phase 3 | Status: COMPLETED